According to DOJ, the company provided consulting services at below market value to certain health care providers that referred patients to NeoGenomics for lab testing.

The firm is developing blood-based early cancer detection tests for a variety of indications, including colorectal cancer and lung cancer.

Burning Rock will add the prostate Genomic Instability Score (prGIS) algorithm to its myChoice HRD Plus assay and will develop new HRD tests on its OncoScreen Plus platform.

The tests are intended for infectious and chronic disease detection and diagnosis as well as to aid in routine health monitoring.

NEW YORK – The Centers for Medicare & Medicaid Services issued a request for information Thursday seeking public input on potential updates to the Clinical Laboratory Improvement Amendments of 1988 ...

The Alzheimer's Drug Discovery Foundation (ADDF) said on Monday that it has partnered with the Michael J. Fox Foundation (MJFF) to develop minimally invasive biomarkers for Parkinson's and Alzheimer's ...

Of the roughly 1 million disputes taken through the law's arbitration process in Q2 2025, around 129,000 were for lab codes, with payments for basic tests averaging hundreds of dollars.

Abbott said on Thursday that its second quarter Diagnostics sales grew 42 percent to $3.09 billion compared to $2.17 billion in the year-ago quarter, helped along by its acquisition of Exact Sciences ...

Under the policy, blood-based tests may be eligible for coverage if they either are cleared or approved by the US FDA or measure phosphorylated-tau 217.

Roche announced on Tuesday that it its Cobas hepatitis D test has been CE marked and the company is launching it in countries that accept the designation. The high-throughput test is intended for the ...

Alamar Biosciences has launched its eMTBR-Tau immunoassay for eMTBR-Tau, a plasma biomarker that is associated with tau-tangle pathology and is being explored as a possible measure of cognitive ...

NEW YORK – Congress on Tuesday passed an appropriations bill that includes a provision to again delay cuts to reimbursements to clinical laboratories under the Protection Access to Medicare Act (PAMA) ...